赛伦生物(688163) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥23,955,839.36, representing a decrease of 3.80% compared to the same period last year[5] - The net profit attributable to shareholders was ¥3,015,115.00, down 23.86% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥1,283,466.89, a decline of 136.95%[5] - The basic and diluted earnings per share were both ¥0.03, reflecting a decrease of 25.00%[6] - The total operating profit for Q1 2023 was CNY 3,604,748, a decline of 18.7% from CNY 4,432,842 in the same period last year[20] - The total comprehensive income for Q1 2023 was CNY 3,015,115, reflecting a decrease from CNY 3,959,972 in the same quarter last year[21] - The net profit attributable to shareholders of the parent company for Q1 2023 was CNY 3,015,115, a decrease of 23.8% compared to CNY 3,959,972 in Q1 2022[21] Cash Flow - Cash flow from operating activities was -¥18,617,864.27, indicating a negative cash flow situation[6] - Cash flow from operating activities showed a net outflow of CNY 18,617,864, worsening from a net outflow of CNY 8,212,503 in Q1 2022[23] - Cash flow from operating activities in Q1 2023 was negative at -¥23,556,243.25, worsening from -¥12,895,985.53 in Q1 2022[32] - The company received cash from investment recovery amounting to ¥465,000,000.00 in Q1 2023, a substantial increase from ¥40,000,000.00 in Q1 2022[32] - The net cash flow from investment activities was negative at CNY -367,115,137, an improvement from CNY -707,982,663 in the previous year[24] - The net cash flow from investment activities was -$362.83 million, a decrease from -$705.89 million in the previous period[33] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,156,028,785.41, a decrease of 0.61% from the end of the previous year[6] - Total assets as of March 31, 2023, were RMB 1,156,028,785.41, slightly down from RMB 1,163,066,774.97 at the end of 2022[16] - Total liabilities decreased to RMB 31,723,218.83 from RMB 41,776,323.39, a reduction of 24.1%[17] - The total liabilities decreased to ¥16,768,864.59 in Q1 2023 from ¥27,268,328.38 in Q1 2022, indicating a significant reduction of 38.5%[27] - The company's total equity increased to RMB 1,124,305,566.58 from RMB 1,121,290,451.58, reflecting a growth of 0.2%[17] - The total equity as of Q1 2023 was ¥1,113,861,779.19, up from ¥1,109,800,236.71 in Q1 2022, reflecting a growth of 0.2%[27] Research and Development - The total R&D investment amounted to ¥3,275,505.96, which is 13.67% of the operating revenue, a slight decrease of 0.12 percentage points[6] - Research and development expenses for Q1 2023 were CNY 3,275,506, slightly down from CNY 3,435,324 in Q1 2022[20] - Research and development expenses for Q1 2023 were ¥3,275,617.75, slightly down from ¥3,435,324.49 in Q1 2022[29] Shareholder Information - The company reported a total of 8,017 common shareholders at the end of the reporting period[11] - The company's accounts receivable increased to ¥15,853,745.94 in Q1 2023 from ¥7,679,770.42 in Q1 2022, indicating a significant rise[26] - Accounts receivable rose to RMB 17,974,753.94 from RMB 7,679,770.42, indicating a significant increase of 134.5%[15] Strategic Focus - The company is focusing on new product development and market expansion strategies to improve future performance[19]